Activity Stream
@moatrx
• 3 weeks ago
Posted a new blog:
US COPD Competitive Intelligence
US COPD Competitive Intelligence
Two 2024 approvals, ensifentrine and dupilumab, ended a decade of inhaler-only competition in the US COPD maintenance market.
Through 2023 the US COPD maintenance...



